ROCKVILLE, Md., Aug. 3, 2023
/PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq:
SHPH), a discovery and development stage specialty pharmaceutical
company focused on improving the outcomes of cancer patients
treated with radiation therapy (RT), today announced that TCG
GreenChem has successfully completed the initial manufacturing
campaign for the active pharmaceutical ingredient (API) of
Ropidoxuridine for use in the Company's upcoming Phase II clinical
trial in brain cancer patients undergoing radiation therapy.
"Shuttle has been working concomitantly with TCG GreenChem to
manufacture API and University of Iowa
Pharmaceuticals to develop the formulation and packaging of the
drug product into capsules for clinical use. Today's announcement
of successfully completing the API manufacturing is an important
step in the advancement Ropidoxuridine, our lead clinical
sensitizer drug candidate, towards the commencement of our upcoming
Phase II clinical trial in brain cancer patients undergoing
radiation therapy," commented Shuttle Pharma's Chairman and CEO,
Anatoly Dritschilo, M.D.
In addition, Shuttle's recent request for a Type B pre-IND
meeting with the FDA for guidance on the proposed Phase II clinical
trial has been approved with a goal of receiving written responses
from the FDA by September 18, 2023.
With this, the Company believes it remains on track to commence its
Phase II clinical study in the fourth quarter of 2023.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements concerning the development of our company.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the "Risk
Factors" section of Shuttle Pharma's Annual Report on Form 10-K for
the year ended December 31, 2022,
filed with the SEC on March 15, 2023,
its Quarterly Report on Form 10-Q for the quarter ended
March 31, 2023, filed with the SEC on
May 25, 2023, as well other SEC
filings. Any forward-looking statements contained in this press
release speak only as of the date hereof and, except as required by
federal securities laws, Shuttle Pharmaceuticals specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-completes-manufacturing-of-active-pharmaceutical-ingredient-api-for-use-in-clinical-trial-301892036.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.